Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitromide SCHEMBL17803670 | 0.98 | CYP3A4 (0.96) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL3087777 | 0.95 | CYP3A4 (0.91) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| Nitromide SCHEMBL9225099 | 0.90 | TSHR (0.81) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL1172383 | 0.88 | SMN1; SMN2 (0.78) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL27970845 | 0.88 | CYP3A4 (0.78) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL3662651 | 0.88 | CYP3A4 (0.78) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL1718794 | 0.88 | CYP3A4 (0.78) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL9798039 | 0.86 | CYP3A4 (0.75) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL7446030 | 0.86 | CYP3A4 (0.75) | CYP3A4SMN1; SMN2TSHRLMNAGAA | |
| SCHEMBL2301797 | 0.86 | CYP3A4 (0.75) | CYP3A4SMN1; SMN2TSHRLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1968 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| CN-110721752-A | Polybenzamide coated Ni-doped Zn2Co3O6Oxygen evolution catalyst and preparation method thereof | 张贵勇 | 2020-01-24 | — | — | CN | claimed |
| CN-110403152-A | A kind of enzyme-linked conjunction of bacterium prepares the preparation method of tuna nutrients biological product | UNIV ZHEJIANG OCEAN | 2019-11-05 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | LOS ALAMOS NAT SECURITY LLC (US) | 2013-09-26 | — | — | US | claimed |
| WO-2013120040-A1 | TARGETED PATHWAY INHIBITION TO IMPROVE MUSCLE STRUCTURE, FUNCTION AND ACTIVITY IN MUSCULAR DYSTROPHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-08-15 | — | — | WO | claimed |
| EP-2616169-A2 | CHROMATOGRAPHY MEMBRANES FOR THE PURIFICATION OF CHIRAL COMPOUNDS | Natrix Separations Inc. (CA) | 2013-07-24 | — | — | EP | claimed |
| US-20130177485-A1 | DIAGNOSTIC DEVICE FOR IDENTIFYING RUPTURE OF MEMBRANE DURING PREGNANCY | MOMTEC LIFE LTD OF YAZMOT HAEMEK (IL) | 2013-07-11 | — | — | US | claimed |
| CN-102871992-A | Application of 3,5-dinitrobenzene formamide in preparation of anti-tuberculosis medicaments | INST MEDICINAL BIOTECHNOLOGY | 2013-01-16 | — | — | CN | claimed |
| US-5985012-A | SELF-POLISHING PAINT COMPRISING ANTIFOULING AGENT AND RESIN VEHICLE COMPRISING VINYL POLYMER HAVING PRIMARY AMINE PENDANT GROUPS BOUND BY REACTION WITH PENDANT CARBONYL GROUPS | NIPPON PAINT CO., LTD. (JP) | 1999-11-16 | — | — | US | claimed |
| JP-2859963-B2 | — | — | 1999-02-24 | — | — | JP | claimed |
| CN-1151695-A | pharmaceutical composition containing benzamide | CENTAUR PHARMACEUTICALS INC (US) | 1997-06-11 | — | — | CN | claimed |
| WO-1996018895-A2 | CHIRAL SEPARATION OF ENANTIOMERS BY HIGH-SPEED COUNTERCURRENT CHROMATOGRAPHY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, ASREPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-20 | — | — | WO | claimed |
| US-5527708-A | MEASURING FLUORESCENCE FROM REACTION OF CREATININE AND 3,5-DINITROBENZOATES OR 3,5-DINITROBENZAMIDE | BLASS KARL G (CA) | 1996-06-18 | — | — | US | claimed |
| EP-0532664-B1 | SUPPORTED CHIRAL LIQUID MEMBRANE FOR THE SEPARATION OF ENANTIOMERS | RES CORP TECHNOLOGIES INC (US) | 1996-02-14 | — | — | EP | claimed |
| EP-0414055-B1 | Acid modified polyarylenesulfides | BAYER AG (DE) | 1995-10-11 | — | — | EP | claimed |
| EP-0670677-A1 | POTENTIATOR OF $i(BACILLUS) PESTICIDAL ACTIVITY | ABBOTT LABORATORIES (US) | 1995-09-13 | — | — | EP | claimed |
| WO-1994009630-A1 | POTENTIATOR OF BACILLUS PESTICIDAL ACTIVITY | NOVO NORDISK ENTOTECH, INC. (US) | 1994-05-11 | — | — | WO | claimed |
| EP-0546390-A1 | Device for creatinine determination | Bayer Corporation (US) | 1993-06-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252945-A1 | AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS | MCOLN1, PYM1, MCOLN2 | CYP3A4 554/4885SMN1; SMN2 1090/4885TSHR 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.